Combinations of paroxetine and 4- (s) - (4-acetyl-piperazin-1-yl) -2- (r)- (4-fluoro-2-methyl- phenyl -piperidine-1-carboxylic acid [1- (r) (3,5-bis-trifluoromethyl-phenyl) -ethyl] methylamide for treatment of depression and / or anxiety
AssigneeGlaxo Group Limited
InventorsRenzo Carletti, Mauro Corsi, Sergio Melotto
Life of this patent
Estimating the term…
Abstract
The present invention relates to therapeutic combinations comprising paroxetine or physiologically acceptable salts or solvates thereof and 4-(S)-(4-Acetyl-piperazin-1-yl)-2-(R)-(4-fluoro-2-methyl-phenyl)-piperidine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide or pharmaceutically acceptable salts or solvates thereof, to pharmaceutical compositions containing said combinations and their use in the treatment of depression and/or anxiety.
Claims18
1-17. (canceled)
A method for the treatment of depression or anxiety in a human in need thereof comprising administering a therapeutically effective combination comprising a dose of each of components:
- a) paroxetine or a physiologically acceptable salt or solvate thereof;
- and
- b) 4-(S)-(4-acetyl-piperazin-1-yl)-2-(R)-(4-fluoro-2-methyl-phenyl)-piperidine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide or a pharmaceutically acceptable salt or solvate thereof,
- wherein said dose of each component is lower than normally expected to produce an effective therapeutic response in the treatment of depression or anxiety in said human, as demonstrated in the gerbil social interaction model.
A pharmaceutical formulation comprising a dose of each of components:
- a) paroxetine or a physiologically acceptable salt or solvate thereof;
- and
- b) 4-(S)-(4-acetyl-piperazin-1-yl)-2-(R)-(4-fluoro-2-methyl-phenyl)-piperidine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide or a pharmaceutically acceptable salt or solvate thereof,
- wherein said dose of each component is lower than normally expected to produce an effective therapeutic response in the treatment of depression or anxiety in said human, as demonstrated in the gerbil social interaction model.
- together with one or more pharmaceutically acceptable carriers or excipients.
Dependencies are inferred from the claim text.